Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Update - Advisory - Unauthorized skin creams and lotions sold at various retailers in Quebec may pose serious health risks


OTTAWA, Aug. 17, 2018 /CNW/ - This advisory has been updated to reflect that Health Canada has seized two unauthorized skin products labelled to contain prescription drugs. Neoprosone Gel Forte was seized from Elikya Canada and Diproson Cream was seized from an additional distributor (Abeit Distributions Inc.)

Original Advisory ? August 1, 2018

Issue
Health Canada seized eight unauthorized skin lotions and creams from Ayotai Canada because they are labelled to contain a prescription drug (clobetasol propionate or betamethasone dipropionate). The unauthorized lotions and creams were distributed by Ayotai and sold by various retailers in Quebec.

Prescription drugs can only be dispensed by a healthcare professional to a patient with a valid prescription. The products listed below have not been evaluated by Health Canada for safety, effectiveness or quality and may pose serious health risks.

Who is affected

Affected product

 

Product Name

Labelled Ingredient

Company

Betasol Cream

clobetasol propionate 0.05%

Ayotai Canada

Betasol Lotion

clobetasol propionate 0.05%

Ayotai Canada

 

Diproson Cream

betamethasone dipropionate 0.05%

Ayotai Canada

 

Abiet Distributions Inc.

(added August 17, 2018)

Haloderm

clobetasol propionate 0.05%

Ayotai Canada

 

L'abdijanaise Cream

clobetasol propionate 0.05%

Ayotai Canada

 

Lemonvate Cream

clobetasol propionate 0.05%

Ayotai Canada

 

Natural Papaya Cream

clobetasol propionate 0.05%

Ayotai Canada

 

Nature Secrète Cream

clobetasol propionate 0.05%

Ayotai Canada

 

Neoprosone Gel Forte

betamethasone dipropionate 0.05%

 

Neomycin sulphate 0.1%

Elikya Canada

(added August 17, 2018)

 

What consumers should do

What Health Canada is doing
Health Canada has seized the products from the company warehouse and has requested the company recall the products already distributed. Should additional retailers or distributors be identified, Health Canada will take appropriate action and inform Canadians as necessary.

Background
Clobetasol propionate is a highly potent topical (applied to the skin) corticosteroid prescription drug used to treat inflammatory skin conditions. It should be used only under the supervision of a health care professional. Side effects include skin irritation, weakening or deterioration. Topical corticosteroids can be absorbed in sufficient amounts to produce adverse effects, including symptoms of adrenal suppression (low blood pressure, low blood sugar, weight loss, muscle pain, gastrointestinal problems, and severe fatigue) or Cushing's syndrome (high blood pressure, high blood sugar, weight gain, muscle weakness, bone loss, and severe fatigue) depending on how much has been absorbed. Clobetasol should not be used by pregnant or nursing women.

Betamethasone dipropionate is a highly potent corticosteroid prescription drug that can be used topically (applied to the skin) to treat inflammatory skin conditions. It should be used only under the supervision of a health care professional. Side effects from topical use include skin irritation and, with prolonged use, skin weakening or deterioration. Topical corticosteroids can be absorbed in sufficient amounts to produce adverse effects, including symptoms of adrenal suppression (low blood pressure, low blood sugar, weight loss, muscle pain, gastrointestinal problems, and severe fatigue) or Cushing's syndrome (high blood pressure, high blood sugar, weight gain, muscle weakness, bone loss, and severe fatigue) depending on how much has been absorbed. Betamethasone dipropionate should not be used by pregnant or nursing women.   

Neomycin sulphate is an antibiotic prescription drug and should be used only under the supervision of a health care professional. Side effects include allergic reactions that range from mild skin reactions (itching, rash and hives) to severe, life-threatening allergic reactions (anaphylaxis). Side effects?such as damage to nerve tissue or the central nervous system, inner ear, and organs responsible for hearing and balance, and reduced kidney function?have occurred in patients taking neomycin orally (by mouth) or when applied on the skin to open wounds or damaged skin. As well, when not used as directed, neomycin sulphate could increase the risk of infections resistant to neomycin or other antibiotics. Neomycin sulphate should not be used by pregnant or breastfeeding women unless directed by a healthcare professional.

Stay connected with Health Canada and receive the latest advisories and product recalls.

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

at 02:48
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...

at 02:00
Amwins Global Risks is delighted to announce Classic Cars and Cotswolds, an auction to raise money for the Matthew Wilson Multiple Myeloma Fund at Blood Cancer UK. The online auction opens today and features Ferraris, Aston Martins, a Rolls Royce, a...

at 01:35
Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...



News published on and distributed by: